In 2018 ISO 10993-1 was released. This new revision of the main biocompatibility standard focused on a risk-based approach for evaluating biocompatibility. It placed an emphasis on the 3Rs of animal testing: reduction, replacement, and refinement.
In 2021 the revolutionary 10993-23 was released, emphasizing the use of an in vitro irritation test over the traditional rabbit irritation test.
In this webinar Thor Rollins, Ron Brown, and Kelly Coleman, Ph.D., will discuss the current status of in vitro testing in the medical device industry, the FDA’s current stance on the testing, the benefits of in vitro alternatives, and the prospect of animal testing in the future.